Vanflyta Now Available for FLT3-ITD Positive Acute Myeloid Leukemia
Vanflyta (quizartinib) is now available for the treatment of newly diagnosed FLT3-ITD positive acute myeloid leukemia.
Source: empr.com
📰 Risk Evaluation News
Page 23 - Risk Evaluation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Risk Evaluation. Real-time updates on events, politics, business and more.
Ammon Bundy, co-defendants to pay $52.5M in Idaho system harassment lawsuit
Jury orders Ammon Bundy, Diego Rodriguez, Peoples Rights Network, Freedom Man Press, and the Bundy campaign for governor to pay $52.5 million in damages for al
United States Diego Rodriguez Chris Roth Ammon Bundy Luke Children At Risk Evaluation Services Freedom Man
Source: beckershospitalreview.com
Vanflyta Approved for Newly Diagnosed FLT3-ITD AML
The FDA has approved Vanflyta (quizartinib) to treat adults with newly diagnosed FLT3-ITD acute myeloid leukemia.
Source: cancertherapyadvisor.com
FDA Approves Quizartinib for Newly Diagnosed AML
Cardiac risks mean the targeted tyrosine kinase inhibitor is available only through a REMS program.
Source: medscape.com
Trends in the Use of Mifepristone for Medical Management of Early Pregnancy Loss From 2016 to 2020
This study assesses the use of mifepristone plus misoprostol for miscarriage management among commercially insured adults in the US.
Jodyw Zylke Merative Marketscan Kristin Walter Commonwealth Fund Department Of Obstetrics Drug Administration Risk Evaluation
Source: jamanetwork.com
Vanflyta Approved for FLT3-ITD Positive Acute Myeloid Leukemia
The FDA has approved Vanflyta (quizartinib) plus chemotherapy for adults with newly diagnosed AML that is FLT3-ITD positive.
Source: empr.com
FDA Roundup: July 21, 2023
/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA Center for...
United States Office Of Generic Drugs Innovative Trial Design Paired Meeting Program Office Of Media Affairs National Evaluation System Daiichi Sankyo Inc
Source: prnewswire.com
A state of conflicting laws
June 24 marked one year since the Supreme Court of the United States overturned Roe v. Wade, complicating abortion law in Wisconsin. Access to the nearby Twin Cities eases abortion
Source: hudsonstarobserver.com
VANFLYTA® First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML
First and only FLT3 inhibitor approved across three phases of AML treatment based on QuANTUM-First results demonstrating VANFLYTA added to chemotherapy improved overall survival Third innovative...
United States Harryp Erba Ken Keller Daiichi Sankyo Division Of Hematologic Malignancies Daiichi Sankyo Company
Source: marketscreener.com
Wrap-Up of Federal and State Chemical Regulatory Developments, July 2023 | Bergeson & Campbell, P.C.
TSCA/FIFRA/TRI - EPA’s Spring 2023 Unified Agenda Includes Proposed And Final TSCA And TRI Rules: EPA’s spring 2023 Unified Agenda, published on June 13, 2023, includes a...
Source: jdsupra.com